Decibel Therapeutics and Cocoon Biotech announced yesterday that the two companies plan to work together to research drug formulations optimized for transtympanic delivery to the ear. The collaboration will make use of Cocoon’s silk fibroin platform and Decibel will have an option to exclusively license the technology on a program-by-program basis. Cocoon is slated to […]
Frequency Therapeutics raises $42m for hearing regeneration drug
Frequency Therapeutics said today that it closed a $42 million Series B round to support the clinical development of its hearing regeneration drug, FX-322. The company is slated to publish top-line data from an ongoing Phase I/II study of FX-322 in the first half of the year. The Series B round was led by Taiwania […]
Intersect ENT launches trial of drug-coated sinus balloon
Intersect ENT (NSDQ:XENT) said today that it enrolled the first patient in a trial of its Ascend drug-coated sinus balloon. The Menlo Park, Calif.-based company’s device is designed to deliver mometasone furoate directly to a person’s sinuses at the time of dilation. The 70-person study is slated to explore whether the Ascend device can reduce inflammation […]
Intersect ENT touts pooled analysis of steroid-releasing sinus implants
Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants. The company’s devices are designed to prop open the sinus ostia following endoscopic sinus surgery. As the implant dissolves, medicine is delivered directly to the sinus lining. The analysis, published in the International Forum […]
Intersect ENT tops estimates with Q3 results
Shares in Intersect ENT (NSDQ:XENT) fell today even though the medical device maker topped expectations on Wall Street with its third-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$7.6 million on sales of $24.7 million for the 3 months ended Sept. 30, for sales growth of 11% compared with the same period […]
Frequency completes enrollment in safety trial for hearing loss drug
Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate. The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in […]
Anthem adds Intersect ENT’s Sinuva implant to formulary
Anthem this month added Intersect ENT‘s (NSDQ:XENT) Sinuva steroid-releasing implant to its updated formulary as a Tier 3 product, according to a note from Leerink analysts. The product is designated on Anthem’s formulary as “LD” – limited distribution – and is only available to certain pharmacies or wholesalers. Intersect ENT launched the product in the […]
Frequency Therapeutics launches clinical trial for hearing loss drug
Frequency Therapeutics said today that the first patients have been treated in a Phase I/II clinical trial to assess its first-in-class drug candidate for hearing restoration. The 24-patient trial is slated to include people with stable sensorineural hearing loss. Participants will receive an injection of Frequency’s FX-322 or a placebo in one ear, with a follow-up […]
Particle Sciences receives patent for device to deliver medication to the tympanic membrane
[PRESS RELEASE] – The Lubrizol Corporation announces its LifeSciences and Particle Sciences businesses, have received a Notice of Allowance on a device for the delivery of medication to the ear-drum. According to Rob Lee, president, Particle Sciences, “This latest patent is a clear-cut demonstration of our staff going beyond formulation to help our clients deliver […]
Intersect ENT shares tumble on Q2 results
Shares in Intersect ENT (NSDQ:XENT) fell today after the medical device maker missed sales expectations on Wall Street with its second-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$4.2 million on sales of $26.3 million for the 3 months ended June 30, for sales growth of 9.7% compared with the same […]
- 1
- 2
- 3
- 4
- Next Page »
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn